abstract |
The present invention relates to a bispecific binding molecule that specifically binds to (i) CD3 and (ii) a surface target antigen on cancer cells, wherein the binding molecule comprises (a) an antibody specifically binding to CD3, and (b) a Fyn-SH3-derived polypeptide binding to a surface target antigen on cancer cells, wherein said Fyn-SH3-derived polypeptide consists of the amino acid sequence of SEQ ID NO: 1, with the proviso that (i) at least one amino acid within amino acids positions 10 to 19 of SEQ ID NO: 1 is substituted, deleted or added, and (ii) at least one amino acid amino acid within amino acids positions 29 to 36 of SEQ ID NO: 1 is substituted, deleted or added, provided that said polypeptide has at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, wherein the determination of identity excludes amino acid positions 12 to 17 and 31 to 34 of SEQ ID NO: 1. |